Epilepsy with Partial Seizures

If you have been diagnosed with Epilepsy with partial seizures and are currently taking up to three medications for its control, you may be eligible to participate in a research study evaluating an investigational medication to be added to your current therapy.


All study-related visits and tests are provided at no cost for the study duration. In addition, epilepsy medication prescribed by the study doctor will be provided to you for six months after you complete the study.


Reimbursement for travel and inconvenience is also provided.

Migraine Study

You could be eligible for a research study that involves completing a survey online to collect information regarding your symptoms, medication use and impacts on your life.

Local doctors are looking for people who experience migraines and who may be taking a preventative medication to treat migraines.

To qualify for this study, you must:

  • Have recently started taking a preventative medication to treat migraines (or will be starting to take one)
  • Be between 18 and 65 years of age
  • Have a history of migraines for 1 year or more prior to the study
  • Have at least 4 days of migraines per month for 3 months prior to the study
  • Meet other study eligibility criteria


If you qualify, compensation will be provided for study participation.


To learn more, please contact:

Onsite Clinical Solutions, Lexington NC
Robert Austin

Limb Spasticity

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem.

Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Nullam dictum felis eu pede mollis pretium. Integer tincidunt. Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim.

Read more